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Characterization of Patients With Axial Spondyloarthritis
by Enthesitis Presence: Data from the Corrona Psoriatic
Arthritis/Spondyloarthritis Registry
Philip J. Mease,1
Alexis Ogdie4

Mei Liu,2 Sabrina Rebello,2 Winnie Hua,2 Robert R. McLean,2 Esther Yi,3 Yujin Park,3 and

Objective. To compare the characteristics of patients with axial spondyloarthritis (axSpA) who had enthesitis
versus those without enthesitis.
Methods. This study included adult patients with axSpA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis
Registry (March 2013 to August 2018). Enthesitis was assessed at enrollment via the Spondyloarthritis Research
Consortium of Canada Enthesitis Index. Characteristics were compared between patients with and without enthesitis
using t tests or Wilcoxon rank-sum tests for continuous variables and χ2 or Fisher exact tests for categorical variables.
Results. Of 477 patients with axSpA, 121 (25.4%) had enthesitis (mean, 3.9 sites) at enrollment. Higher proportions
of patients with enthesitis were female and had nonradiographic axSpA than those without enthesitis (both P < 0.05).
Additionally, higher proportions of patients with enthesitis had prior biologic (38.8% vs 27.2%) and conventional
synthetic disease-modifying antirheumatic drug (csDMARD; 24.8% vs 13.3%) use and were currently receiving a
combination of biologics and csDMARDs (28.6% vs 18.1%) than those without enthesitis. Patients with enthesitis had
worse disease activity (tender and swollen joint counts, physician global assessment, Ankylosing Spondylitis Disease
Activity Score, Bath Ankylosing Spondylitis Disease Activity Index, and Bath Ankylosing Spondylitis Functional Index),
spinal mobility, and quality of life (pain, fatigue, Health Assessment Questionnaire, and EuroQol visual analog scale
scores); greater work impairment; and had a history of depression and fibromyalgia than those without enthesitis (all
P < 0.05).
Conclusion. In this US-based real-world study, enthesitis in patients with axSpA was associated with worse
disease activity and quality of life than those with no enthesitis.
INTRODUCTION
Spondyloarthritis (SpA) comprises a group of rheumatic
 iseases that include ankylosing spondylosis (AS), reactive arthrid
tis, psoriatic arthritis (PsA), juvenile SpA, and arthritis and spondylitis associated with inflammatory bowel disease, such as

 lcerative colitis and Crohn disease (1). SpA with predominantly
u
axial involvement is termed axial SpA (axSpA) and is classified
into two subgroups based on presence (AS) or absence (nonradiographic axSpA [nr-axSpA]) of radiographic sacroiliitis (1).
Enthesitis, defined as inflammation of tendon, ligament, or joint
capsule insertion sites into bone, or entheses, commonly occurs
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in patients with SpA (2). Enthesitis may be among the first symptoms of SpA (3) and was identified as a unique feature of SpA
that could differentiate this group of rheumatic diseases from
rheumatoid arthritis (RA) (4). Enthesitis predominantly occurs in
extra-articular structures prone to inflammation in SpA diseases,
whereas RA is characterized by intra-articular inflammation of
the synovial membrane; both enthesitis and synovitis can occur
simultaneously or independently of one another (2).
Enthesitis is a key clinical feature of SpA, with or without
axial involvement (5). Among patients with AS and nr-axSpA,
the prevalence of enthesitis is reportedly 34% to 74% (6-8) and
35.4% (7), respectively. However, enthesitis is often underdiagnosed, and quantification of peripheral enthesitis in routine
clinical practice lacks specificity and sensitivity (9,10). Enthesitis is commonly observed in the lower extremities of patients
with SpA, particularly the heel (11). In addition to the Achilles
and plantar fascia insertions, other frequently observed sites of
enthesitis include muscle attachments to the greater and lesser
trochanters, insertion of the quadriceps tendon at the upper
patellar pole, and insertions of the flexor and extensor tendons
at the phalanges (9,11).
Clinical evaluation of enthesitis is challenging. Correlation
between clinical examination of tenderness at entheseal insertion
sites and imaging techniques for evidence of entheseal inflammation is low (12). In addition, enthesis sites are not readily accessible to biopsy for verification of inflammatory change, unlike the
synovium, skin, or gut; hence, physical examination of entheseal
insertion sites may not reflect true inflammatory change but could
reveal variable pain thresholds and the phenomenon of central
sensitization (13). Despite its frequent occurrence among patients
with axSpA and its correlation with disease severity, enthesitis is
primarily evaluated as a secondary endpoint in randomized clinical
trials or not evaluated at all (14-16).
There are limited real-world studies on the characteristics of
patients with axSpA and enthesitis. Additionally, relatively little is known
about the impact of enthesitis on these patients. In this US-based
study, we sought to compare the characteristics of patients with
axSpA who had physical evidence of enthesitis with those of patients
without enthesitis. Because imaging methods were not used to verify
the presence of enthesitis, the results reported in our study describe
the characteristics and impact of clinical enthesitis.

METHODS
Data source. The Corrona PsA/SpA Registry is a large,
independent, prospective, observational cohort of patients
diagnosed with PsA or SpA by a rheumatologist. Patients were
recruited from 44 private and academic practice sites across 27
states in the United States, with 46 participating rheumatologists. As of June 2019, data on approximately 3939 patients
with PsA/SpA had been collected. The Corrona PsA/SpA Registry includes information on 15 806 patient visits and approx-
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imately 8423 patient-years of follow-up, with a mean patient
follow-up of 2.9 years (median, 2.4 years).
All participating investigators were required to obtain full board
approval for conducting noninterventional research with a limited
data set involving human participants. The Corrona PsA/SpA Registry and its investigators have been reviewed and approved by a
central institutional review board (IRB; New England Independent
Review Board No. 120160070). For academic investigative sites
that did not receive a waiver to use the central IRB, approval was
obtained from the respective governing IRBs. All research was
conducted in compliance with the current (2013) Declaration of
Helsinki. All registry participants were required to provide written
informed consent and authorization prior to participating.
Study design and population. This cross-sectional
observational study included all patients aged 18 years or older
enrolled in the Corrona PsA/SpA Registry between March 2013
and August 2018 who had rheumatologist-diagnosed axSpA (AS
or nr-axSpA) according to the Assessment of Spondyloarthritis
International Society classification criteria (17,18). Patients who
had a concomitant PsA diagnosis were excluded.
Patients were stratified by the presence or absence of clinical enthesitis at registry enrollment. Patients were classified as
having enthesitis (yes/no) at any site using the Spondyloarthritis
Research Consortium of Canada (SPARCC) Enthesitis Index,
a measure of enthesitis based on presence of tenderness at 16
entheseal sites (19). The SPARCC Enthesitis Index assesses nine
bilateral sites: medial epicondyle, lateral epicondyle, supraspinatus insertion into greater tuberosity of humerus, greater trochanter,
quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle, Achilles tendon insertion into calcaneum, and plantar fascia insertion
into calcaneum. For scoring purposes, the inferior patella and tibial tuberosities were considered one site due to their anatomical
proximity. Tenderness was recorded as present (ie, one) or absent
(ie, zero) at each site. The sites were summed with the overall
score ranging from 0 to 16; a score of 0 is indicative of absence
of enthesitis, whereas patients with a score greater than 0 were
classified as having enthesitis.
Outcomes and assessments. Data were collected at
the registry enrollment visit and included patient demographics
(age, sex, race/ethnicity, marital status, and patient-reported
work status), clinical characteristics (physician-reported history
of comorbidities and disease and symptom duration), treatment
profiles (prior and current biologic and conventional synthetic
disease-modifying antirheumatic drug [csDMARD] use), disease activity measures (Ankylosing Spondylitis Disease Activity
Score [ASDAS], Bath Ankylosing Spondylitis Disease Activity
Index [BASDAI], Bath Ankylosing Spondylitis Functional Index
[BASFI], C-reactive protein [CRP] level, erythrocyte sedimentation
rate [ESR], tender joint count [TJC], swollen joint count [SJC],
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Table 1. Baseline demographics of patients with axSpA at
enrollment, stratified by enthesitis status
Patients with axSpAa

Characteristic
Nonradiographic axSpA, n (%)
Age, mean (SD), yearsc
Female, n (%)
White, n (%)
Attended college/university, n (%)
Private insurance, n (%)
Work status, n (%)
Full time
Part time
Disabled
Retired
Other
BMI, mean (SD), kg/m2
BMI (in kg/m2) categories, n (%)
Normal/underweight (<25)
Overweight (25 to <30)
Obese (≥30)

With
No
P
enthesitis enthesitis
(n = 121) (n = 356) valueb
34 (28.1)
47.3 (13.1)
61 (50.4)
105 (88.2)
92 (76.7)
96 (82.1)
n = 121
69 (57.0)
7 (5.8)
24 (19.8)
12 (9.9)
9 (7.4)
29.9 (6.9)
n = 120
33 (27.5)
33 (27.5)
54 (45.0)

56 (15.7)
47.3 (14.1)
112 (31.9)
319 (92.7)
236 (67.0)
276 (81.9)
n = 351
214 (61.0)
22 (6.3)
42 (12.0)
44 (12.5)
29 (8.3)
29.8 (6.8)
n = 345
86 (24.9)
116 (33.6)
143 (41.4)

<0.01
0.99
<0.01
0.16
0.09
0.12
0.30

0.83
0.46

Abbreviation: axSpA, axial spondyloarthritis; BMI, body mass index.
a
All values were calculated based on available data and had less than
20% missing data.
b
P value for comparison between patients with versus those without
enthesitis. The Wilcoxon rank-sum test was used for continuous
variables, whereas the χ2 test was used for categorical variables. For
variables where more than 20% of the cells had expected counts less
than five, the Fisher exact test was used.
c
t test for age comparison between pairs of groups.

SPARCC Enthesitis Index, dactylitis count, and physician global
assessment), quality of life measures (patient global assessment
visual analog scale [VAS], patient-reported pain and fatigue,
Health Assessment Questionnaire Disability Index [HAQ-DI], HAQ
for the Spondyloarthropathies [HAQ-S] (20), EuroQol Quality of
Life VAS [EQ-VAS], and EuroQol 5-dimension scale [EQ-5D]),
and work productivity measures (Work Productivity and Activity
Impairment questionnaire).
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Moderate positive correlations between obesity or higher
body mass index (BMI) and enthesitis counts in patients with
axSpA and PsA have been observed in previous studies (21-24).
To explore a potential relationship between obesity and enthesitis
at specific sites in our study population, we evaluated the prevalence of enthesitis at each SPARCC enthesitis site among patients,
with enthesitis stratified by BMI category (normal/underweight,
BMI < 25 kg/m2; overweight, BMI 25 to < 30 kg/m2; obese, BMI
≥ 30 kg/m2).
Data analysis. Means and frequencies of characteristics
in all patients with positive enthesitis scores were compared with
those in patients without positive enthesitis scores (reference
group) using χ2 or Fisher exact tests for categorical variables and
t tests or Wilcoxon rank-sum tests for continuous variables.

RESULTS
Baseline patient demographics, clinical characteristics, and treatment profiles. A total of 477 patients with
axSpA met the inclusion criteria. The majority of patients were
white, overweight (mean BMI, 29 kg/m2), worked full time, and
had private insurance (Table 1). Overall, 121 patients (25.4%) had
enthesitis and 356 (74.6%) did not. The prevalence of enthesitis
at each site (mean, 3.9 sites) among patients with enthesitis is
shown in Figure 1). Enthesitis was most prevalent in the greater
trochanter (43.8%) followed by the lateral epicondyle (43.0%) and
supraspinatus insertion into the greater tuberosity of the humerus
(34.7%). There was no significant relationship between BMI categories and presence of enthesitis (Supplementary Table 1).
Higher proportions of patients with enthesitis were female
and had nr-axSpA than those without enthesitis (both P < 0.05;
Table 1). Patients with enthesitis were more likely to have a history of depression, serious infections, and fibromyalgia than
those without enthesitis (all P < 0.05; Table 2). With regard to

Figure 1. Distribution of enthesitis sites among patients with axial spondyloarthritis. aPercentages listed are a total of the left and right affected
sites. bFor scoring purposes, the inferior patella and tibial tuberosities are considered one site due to their anatomical proximity.

452

|

MEASE ET AL

Table 2. Baseline clinical characteristics and treatment history of
patients with axSpA at enrollment, stratified by enthesitis status

Patients with axSpAa

Characteristic
Symptom duration, mean (SD), y
Disease duration, mean (SD), y
History of comorbidities, n (%)
Cardiovascular disease
Hypertension
Depression
Hyperlipidemia
Uveitis
Metabolic syndrome
Psoriasis
Diabetes mellitus
Ulcerative colitis
Serious infections
Any cancer (excluding NMSC)
Crohn disease
Fibromyalgia
Anxiety
History of prior biologic use, n (%)
No. of prior biologics used, n (%)
0
1
≥2
History of prior csDMARD use,
n (%)
No. of prior csDMARDs used,
n (%)
0
1
≥2
Current biologic use, n (%)
TNFi use
Monotherapy
Combination therapy
Non-TNFi use
Monotherapy
Combination therapy
Current overall csDMARD use,
n (%)c
Current csDMARD use only
(without biologic or
tsDMARD use), n (%)

With
No
P
enthesitis enthesitis
(n = 121) (n = 356) valueb
17.3 (13.1)
8.2 (10.3)

16.8 (11.8)
10.2 (10.7)

0.67
0.09

56 (46.3)
37 (30.6)
29 (24.0)
21 (17.4)
13 (10.7)
9 (7.4)
7 (5.8)
11 (9.1)
3 (2.5)
12 (9.9)
5 (4.1)
6 (5.0)
11 (9.1)
6 (5.0)
47 (38.8)

140 (39.3)
109 (30.6)
53 (14.9)
52 (14.6)
40 (11.2)
27 (7.6)
22 (6.2)
20 (5.6)
18 (5.1)
16 (4.5)
16 (4.5)
14 (3.9)
11 (3.1)
7 (2.0)
97 (27.2)

74 (61.2)
26 (21.5)
21 (17.4)
30 (24.8)

259 (72.8)
68 (19.1)
29 (8.1)
47 (13.2)

0.18
0.99
0.02
0.47
0.88
0.96
0.88
0.18
0.31
0.03
0.87
0.63
0.01
0.08
0.02
0.01

<0.01

patients currently receiving a tumor necrosis factor inhibitor
(TNFi), a higher proportion of patients with enthesitis were receiving a TNFi in combination with csDMARDs than those without
enthesitis (28.6% vs 18.1%).
Baseline disease activity measures. Patients with
enthesitis had worse disease activity than those without enthesitis, including higher mean TJC (8.2 vs 1.3) and SJC (1.3 vs 0.5);
higher ASDAS (2.9 vs 2.5), BASDAI (5.3 vs 4.1), BASFI (4.5 vs
3.3), and physician global assessment (36.6 vs 23.5) scores;
and more restricted spinal mobility as measured by mean lateral
lumbar flexion (28.1 vs 21.5 cm) (all P < 0.05; Table 3). Additionally,
patients with enthesitis had lower CRP levels (6.9 vs 10.4 mg/L)
and ESR (14.2 vs 15.5 mm/h) than those without enthesitis, but
these differences were not statistically significant (Table 3).
Baseline patient-reported outcome measures and
work productivity. Patients with enthesitis had worse quality
of life than those without enthesitis, including higher mean pain
(57.5 vs 43.5), fatigue (56.5 vs 45.0), HAQ-DI (0.9 vs 0.6), and
HAQ-S (0.9 vs 0.6) scores; additionally, they had a lower EQ-VAS
score at enrollment (59.7 vs 66.4), indicating a worse health state
(all P < 0.01; Table 4). With regard to work productivity and activity impairment, patients with enthesitis had a significantly greater

0.01
91 (75.2)
22 (18.2)
8 (6.6)
84 (69.4)

309 (86.8)
37 (10.4)
10 (2.8)
237 (66.6)

55 (71.4)
22 (28.6)

185 (81.9)
41 (18.1)

Table 3. Baseline disease activity measures in patients with axSpA
at enrollment, stratified by enthesitis status
Patients with axSpAa

0.56
0.05

Characteristic
0.47

6 (100)
0
34 (28.1)

6 (75)
2 (25)
72 (20.2)

0.07

12 (9.9)

30 (8.4)

0.62

Abbreviation: axSpA, axial spondyloarthritis; csDMARD, conventional
synthetic disease-modifying antirheumatic drug; NMSC, nonmel
anoma skin cancer; TNFi, tumor necrosis factor inhibitor; tsDMARD,
targeted synthetic disease-modifying antirheumatic drug.
a
All values were calculated based on available data and had less than
20% missing data.
b
P value for comparison between patients with versus those without
enthesitis. The Wilcoxon rank-sum test was used for continuous
variables, whereas the χ2 test was used for categorical variables. For
variables where more than 20% of the cells had expected counts less
than 5, the Fisher exact test was used.
c
A patient may be on multiple csDMARDs.

treatment, higher proportions of patients with enthesitis had a
history of prior biologic (38.8% vs 27.2%) and csDMARD (24.8%
vs 13.2%) use than those without enthesitis (both P < 0.05;
Table 2). The proportion of patients currently receiving biologic
therapy was comparable between groups. However, among

ASDAS
BASDAI (0-10)
BASFI (0-10)
Tender joint count (0-68)
Swollen joint count (0-66)
Dactylitis, n (%)
Dactylitis (1-20)
SPARCC Enthesitis Index (1-16)
Inflammatory back pain, n (%)
Lateral lumbar flexion (average
of left and right), cm
CRP, mg/L
ESR, mm/h
Physician global assessment

With
enthesitis
(n = 121)

No
enthesitis
P
(n = 356) valueb

2.9 (0.9)
5.3 (2.2)
4.5 (2.8)
8.2 (10.8)
1.3 (3.3)
4 (3.3)
2.0 (2.0)
3.9 (2.9)
78 (64.5)
28.1 (21.1)

2.5 (1.2)
4.1 (2.4)
3.3 (2.7)
1.3 (4.2)
0.5 (2.0)
7 (2.0)
3.6 (3.9)
0
205 (57.6)
21.5 (18.8)

<0.01
<0.01
<0.01
<0.01
<0.01
0.40
0.35
…
0.18
0.01

6.9 (7.0)
14.2 (16.4)
36.6 (21.9)

10.4 (24.1)
15.5 (18.9)
23.5 (21.9)

0.32
0.84
<0.01

Abbreviation: ASDAS, Ankylosing Spondylitis Disease Activity Score;
axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional
Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate;
SPARCC, Spondyloarthritis Research Consortium of Canada.
a
All values were calculated based on available data and are presented
as mean (SD) unless otherwise stated and had less than 20% missing
data except for ESR and CRP.
b
P value for comparison between patients with versus those without
enthesitis. The Wilcoxon rank-sum test was used for continuous
variables, whereas the χ2 test was used for categorical variables. For
variables where more than 20% of the cells had expected counts less
than 5, the Fisher exact test was used.
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Table 4. Baseline patient-reported outcome measures in patients
with axSpA at enrollment, stratified by enthesitis status
Patients with axSpAa

Characteristic
Patient pain (VAS 0-100)
Patient fatigue (VAS 0-100)
Patient global assessment
(VAS 0-100)
HAQ-DI (0-3)
HAQ-S (0-3)
EQ-5D (0-1)
EQ (VAS 0-100): patient
health today
WPAI-GH domains
% Work time missed
% Impairment while
working
% Overall work impairment
% Activity impairment
Current employment, n (%)
Morning stiffness, n (%)
<30 min
≥30 min

With
enthesitis
(n = 121)

No
enthesitis
(n = 356)

P
valueb

57.5 (26.7)
56.5 (27.5)
49.8 (29.7)

43.5 (29.5)
45.0 (28.6)
54.1 (32.9)

<0.01
<0.01
0.56

0.9 (0.7)
0.9 (0.7)
0.7 (0.2)
59.7 (22.7)

0.6 (0.6)
0.6 (0.6)
0.7 (0.2)
66.4 (22.0)

<0.01
<0.01
<0.01
<0.01

9.0 (18.8)
38.3 (27.4)

5.8 (16.8)
25.3 (24.4)

0.06
<0.01

41.4 (29)
49.8 (29.5)
75 (63.0)
n = 117
28 (23.9)
89 (76.1)

27.6 (26.6)
35.6 (29.3)
241 (68.7)
n = 318
71 (22.3)
247 (77.7)

<0.01
<0.01
0.26
0.72

Abbreviation: axSpA, axial spondyloarthritis; EQ-5D, EuroQol
5-dimension questionnaire; HAQ-DI, Health Assessment Ques
tionnaire Disability Index; HAQ-S, Health Assessment Questionnaire
for the Spondyloarthropathies; VAS, visual analog scale; WPAI-GH,
Work Productivity and Activity Impairment Questionnaire-General
Health.
a
All values were calculated based on available data and are presented
as mean (SD) unless otherwise stated and had less than 20% missing
data except for patient global assessment, HAQ-DI, HAQ-S, and
WPAI-GH1 to WPAI-GH3.
b
P value for comparison between patients with versus those without
enthesitis. The Wilcoxon rank-sum test was used for disease activity
measurements, whereas the χ2 test was used for categorical
variables.

percentage of impairment while working (38.3% vs 25.3%),
percentage of overall work impairment (41.4% vs 27.6%), and
percentage of activity impairment (49.8% vs 35.6%) than those
without enthesitis (all P < 0.01).

DISCUSSION
In this US-based real-world study of patients with axSpA, the
presence of clinical enthesitis was associated with higher disease
activity and worse quality of life than the absence of enthesitis.
We also found that patients with enthesitis were more likely to be
receiving combination therapy, further suggesting that this population had more severe or burdensome disease. These results
are consistent with previous studies showing that presence of
enthesitis in patients with axSpA is correlated with increased disease severity and poorer quality of life (25-27). Additionally, consistent with previous reports (27-29), we observed more frequent
enthesitis among female patients (50%) versus male patients
(32%). Presence of enthesitis in patients with PsA has been linked
to axial and peripheral joint damage, likelihood of developing joint
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ankyloses, overall higher disease activity, more pain, worse quality of life and functional status, sleep disturbance, and patient-reported pain and fatigue (30-32). Additionally, in PsA, enthesitis has
been regarded as a predictor of poor disease outcomes and may
represent a lower probability of achieving remission and low disease activity (22,30).
The higher prevalence of pain or tenderness at entheseal
sites among female patients with axSpA may contribute to the
greater disease burden in female than in male patients, despite
slower radiographic progression in female patients (27-29). However, in painful chronic disorders, pain can result not only from
inflammation and mechanical irritation but from a combination
of mechanisms, including central sensitization, which is defined as
amplification of neural signaling that leads to pain hypersensitivity
(33). Central sensitization contributes to the pain hypersensitivity phenotype of several disorders, including fibromyalgia, which
represents a state of persistent central sensitization (13,33). The
American College of Rheumatology introduced fibromyalgia classification criteria in 1990 based on the scoring of 11 out of 18 tender points (34); these sites overlap with those often assessed for
enthesitis (35). Subsequent iterations of the criteria have removed
the tender points assessment, but evaluation of tender points is
still commonly performed in clinical practice (36). Because central
pain sensitization likely occurs in some patients with axSpA and
is associated with higher disease activity (37), patient-reported
outcome measures may be amplified by presence of fibromyalgia, which can occur along with axSpA. As in our study, the
proportion of women with fibromyalgia in previous studies of
patients with axSpA was higher than that of men (13). Because
enthesitis was defined in our study as presence of tenderness
at 18 entheseal points based on physical examination without
ultrasound or magnetic resonance imaging (MRI) corroboration
of inflammation, the difference in frequency between men and
women may partially reflect a higher prevalence of central sensitization in women, which correlated with symptoms such as higher
TJC, depression, and fatigue. Therefore, distinguishing fibromyalgia from axSpA is important and may be addressed using currently available patient-reported outcome tools for fibromyalgia,
such as the Widespread Pain Index and Symptom Severity Score
or the Fibromyalgia Rapid Screening Tool (36). However, it may
be challenging to differentiate entheseal site tenderness due to
inflammatory enthesitis from tenderness due to central sensitization using only clinical examination; thus, more specific tools for
diagnosis of fibromyalgia or central sensitization are needed, such
as validated questionnaires as mentioned above and/or advanced
imaging techniques, including ultrasound or MRI of the entheses,
neuroimaging techniques, or quantitative sensory testing (13).
Because enthesitis may be one of the pivotal pathological processes in SpA associated with poor disease outcomes
(30,38), detection of early enthesitis lesions may be critical for
SpA diagnosis. MRI has shown that extracapsular inflammation
of joints represents enthesitis with varying extents of soft tissue
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and bone marrow edema (39,40). Recently, Poggenborg and colleagues demonstrated the utility of whole-body MRI in the detection of subclinical axial and peripheral enthesitis (41). Detection of
enthesitis using ultrasound has also been useful, particularly for
early diagnosis of SpA (42).
Several indices are available for clinical measurement of
inflammatory activity and treatment response of enthesitis in
axSpA and peripheral SpA. The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), University of California, San
Francisco Index, and Berlin Index have been used in axSpA
studies (43-45). MASES was initially developed for identification of entheses specific for axial disease in AS (46) and has
performed well in many AS and axSpA trials (45,47,48). The
SPARCC Enthesitis Index was initially developed for use in both
axial and peripheral SpA, including PsA (19). Although it has
principally been used in PsA and has not been used in axSpA
clinical trials, we have successfully used the SPARCC Enthesitis Index for enthesitis evaluation in previous studies of patients
with axSpA (30,49-51).
The SPARCC Enthesitis Index has been used in several PsA
clinical trials with success (52-54). An additional index, the Leeds
Enthesitis Index (LEI), was developed for enthesitis assessment
in PsA (55). In the ABILITY-2 trial, which assessed the efficacy of
adalimumab in patients with peripheral SpA, the LEI, SPARCC,
and MASES indices were compared for their discriminatory
capacity in assessing enthesitis and treatment response; the LEI
and SPARCC Enthesitis Index outperformed the MASES, most
likely because the MASES primarily evaluates axial sites, whereas
the LEI and SPARCC Enthesitis Index evaluate more peripheral
sites (46).
This study has some limitations that should be considered.
Patients enrolled in this study are routinely seen and treated by
rheumatologists voluntarily participating in the Corrona PsA/SpA
Registry and may not be representative of all US patients with
axSpA. Because presence of enthesitis in our study was based on
physical examination without imaging corroboration, we cannot
truly distinguish between central sensitization, as characterized by
tender entheseal sites, and enthesitis. Accordingly, our findings
describe features and impact of clinical enthesitis. Additionally, the
presence of depression and fibromyalgia was based on investigator judgement and was not objectively measured. Going forward, the Corrona Registry will be incorporating the Widespread
Pain Index and Symptom Severity Scale, a validated quantitative
tool to measure central sensitization (36,56), to provide a more
objective assessment of the presence and impact of central sensitization in future analyses. All comparisons were descriptive;
no adjustments were made to account for differences in patient
characteristics, such as age and sex, which may have influenced
the other differences observed between patients with and those
without enthesitis.
In conclusion, enthesitis was associated with greater overall burden of axSpA, including worse disease activity and quality
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of life. Enthesitis may represent the primary underlying process
for SpA diseases, such as axSpA. Therefore, identification, evaluation, and management of enthesitis is critical to ameliorate the
overall burden of disease. Additionally, more research is needed
to guide treatment options specific to enthesitis and to better discriminate between enthesitis and central sensitization.
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